Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZA017)

Drug Name
Tetracycline Drug Info
Synonyms
Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
54675776
ChEBI ID
CHEMBL27902
CAS Number
CAS 60-54-8
TTD Drug ID
D08NQZ
VARIDT Drug ID
DR00127
ACDINA Drug ID
D00668

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glycine, serine and threonine metabolism 2.62 0.00e+0 31/40 (77.5%) PSAT1;PHGDH;CBS;...
Cysteine and methionine metabolism 2.26 0.00e+0 43/50 (86%) PSAT1;PHGDH;CBS;...
One carbon pool by folate 2.25 0.00e+0 15/20 (75%) MTHFD2;SHMT2;MTHFD1;...
Phenylalanine metabolism 2.20 0.00e+0 14/17 (82.35%) GOT1;HPD;ALDH3A1;...
Tryptophan metabolism 2.10 2.13e-3 35/42 (83.33%) IDO1;TDO2;ALDH2;...
Ferroptosis 2.09 1.77e-3 36/41 (87.8%) SLC7A11;SLC3A2;STEAP3;...
Tyrosine metabolism 2.06 1.52e-3 30/36 (83.33%) GOT1;HPD;ADH1C;...
Histidine metabolism 1.96 6.66e-3 16/22 (72.73%) ALDH2;ALDH3A1;MAOA;...
Folate biosynthesis 1.96 5.92e-3 23/26 (88.46%) MOCOS;AKR1C3;GGH;...
Ascorbate and aldarate metabolism 1.95 6.39e-3 15/30 (50%) ALDH2;UGT2A3;RGN;...
Retinol metabolism 1.94 5.81e-3 41/68 (60.29%) ADH1C;ADH5;CYP3A4;...
Alanine, aspartate and glutamate metabolism 1.92 6.21e-3 27/37 (72.97%) ASNS;ASS1;GFPT1;...
Pentose and glucuronate interconversions 1.85 1.06e-2 17/34 (50%) AKR1B10;SORD;AKR1B1;...
Valine, leucine and isoleucine degradation 1.85 1.06e-2 42/48 (87.5%) ALDH6A1;ALDH2;PCCB;...
Drug metabolism 1.83 1.21e-2 78/151 (51.66%) ADH1C;ADH5;GSTT1;...
Cell cycle 1.80 1.53e-2 110/124 (88.71%) CDC20;MYC;TP53;...
Porphyrin and chlorophyll metabolism 1.80 1.44e-2 23/43 (53.49%) CP;HMOX1;BLVRB;...
beta-Alanine metabolism 1.78 1.83e-2 25/30 (83.33%) ALDH6A1;ALDH2;ALDH3A1;...
Arginine biosynthesis 1.78 1.85e-2 17/22 (77.27%) ASS1;GOT1;CPS1;...
Fatty acid degradation 1.75 2.72e-2 40/43 (93.02%) ADH1C;ADH5;ALDH2;...
Glyoxylate and dicarboxylate metabolism 1.74 2.84e-2 23/30 (76.67%) SHMT2;GLDC;SHMT1;...
Glutathione metabolism 1.73 3.05e-2 43/57 (75.44%) CHAC1;LAP3;GCLM;...
Metabolism of xenobiotics by cytochrome P450 1.73 2.92e-2 49/77 (63.64%) EPHX1;ADH1C;ADH5;...
Inositol phosphate metabolism 1.73 2.97e-2 66/73 (90.41%) ALDH6A1;INPP4B;INPP5A;...
Complement and coagulation cascades 1.72 2.85e-2 76/85 (89.41%) FGB;SERPINA1;C5;...
Homologous recombination 1.72 2.91e-2 35/41 (85.37%) RBBP8;POLD2;NBN;...
Synthesis and degradation of ketone bodies 1.70 3.35e-2 9/10 (90%) HMGCL;BDH2;OXCT1;...
Lysine degradation 1.68 3.54e-2 51/63 (80.95%) ALDH2;EHHADH;KMT5B;...
Fanconi anemia pathway 1.66 3.89e-2 36/54 (66.67%) USP1;HES1;FANCI;...
Mineral absorption 1.64 4.19e-2 48/60 (80%) MT1E;MT1G;MT1F;...
Arrhythmogenic right ventricular cardiomyopathy -1.67 4.47e-2 70/77 (90.91%) ITGA10;ITGAV;SGCD;...
Dilated cardiomyopathy -1.72 3.16e-2 86/96 (89.58%) PRKACA;ADCY2;ITGA10;...
Endocytosis -1.73 3.20e-2 198/252 (78.57%) SH3GL1;ARPC5L;ACTR3;...
Prion disease -1.73 3.60e-2 209/273 (76.56%) CASP9;HSPA2;BAD;...
Huntington disease -1.74 3.98e-2 233/306 (76.14%) COX4I1;KIF5B;DNAI2;...
Diabetic cardiomyopathy -1.78 3.40e-2 162/203 (79.8%) NDUFA9;NCF4;NDUFB2;...
Hypertrophic cardiomyopathy -1.89 1.48e-2 81/90 (90%) ITGA10;PRKAB2;ITGAV;...
Legionellosis -1.90 1.62e-2 51/57 (89.47%) TLR2;IL12A;CLK4;...
Cardiac muscle contraction -2.03 3.09e-3 64/87 (73.56%) CACNA1S;CACNA2D3;CACNG4;...
Phagosome -2.11 4.64e-3 118/152 (77.63%) DYNC2H1;CLEC7A;ATP6V0D1;...
Oxidative phosphorylation -2.32 0.00e+0 93/133 (69.92%) ATP4A;ATP6V0D1;NDUFB3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM - 20uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM - 20uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 40uM 3H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM - 20uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H